Pictet Asset Management Holding SA trimmed its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 129,472 shares of the company’s stock after selling 12,741 shares during the period. Pictet Asset Management Holding SA’s holdings in CRISPR Therapeutics were worth $7,241,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of the company. Privium Fund Management B.V. raised its position in CRISPR Therapeutics by 8.9% during the 3rd quarter. Privium Fund Management B.V. now owns 48,974 shares of the company’s stock worth $2,709,000 after buying an additional 4,000 shares during the last quarter. Pekin Hardy Strauss Inc. purchased a new stake in shares of CRISPR Therapeutics in the third quarter valued at about $1,481,000. Kestra Advisory Services LLC boosted its holdings in shares of CRISPR Therapeutics by 16.1% in the third quarter. Kestra Advisory Services LLC now owns 20,068 shares of the company’s stock valued at $1,110,000 after acquiring an additional 2,776 shares in the last quarter. Quadcap Wealth Management LLC boosted its holdings in shares of CRISPR Therapeutics by 20.9% in the third quarter. Quadcap Wealth Management LLC now owns 5,739 shares of the company’s stock valued at $317,000 after acquiring an additional 992 shares in the last quarter. Finally, Compass Financial Management LLC purchased a new stake in shares of CRISPR Therapeutics in the third quarter valued at about $25,000. 69.20% of the stock is owned by institutional investors and hedge funds.
CRISPR Therapeutics Stock Performance
Shares of CRSP stock opened at $42.24 on Monday. The business’s fifty day moving average price is $52.09 and its 200 day moving average price is $52.54. CRISPR Therapeutics AG has a 1-year low of $41.75 and a 1-year high of $63.45. The firm has a market capitalization of $4.10 billion, a PE ratio of -8.91 and a beta of 1.92. The company has a debt-to-equity ratio of 0.36, a current ratio of 16.21 and a quick ratio of 16.21.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last released its earnings results on Monday, November 2nd. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.09). CRISPR Therapeutics had a negative net margin of 1,812.07% and a negative return on equity of 25.59%. The business had revenue of $12.67 million during the quarter, compared to analyst estimates of $14.75 million. CRISPR Therapeutics’s quarterly revenue was up 1311.1% compared to the same quarter last year. As a group, sell-side analysts forecast that CRISPR Therapeutics AG will post -4.54 EPS for the current fiscal year.
Insider Activity at CRISPR Therapeutics
In other news, General Counsel James R. Kasinger sold 10,400 shares of the company’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $60.24, for a total transaction of $626,496.00. Following the transaction, the general counsel directly owned 94,784 shares of the company’s stock, valued at $5,709,788.16. This represents a 9.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Simeon George sold 14,514 shares of the stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $49.63, for a total transaction of $720,329.82. Following the completion of the transaction, the director owned 15,486 shares of the company’s stock, valued at $768,570.18. This represents a 48.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 93,558 shares of company stock valued at $4,881,663. Company insiders own 5.20% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on CRSP. Piper Sandler reiterated an “overweight” rating and set a $110.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, November 10th. Wells Fargo & Company reduced their price objective on shares of CRISPR Therapeutics from $75.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 4th. Citizens Jmp restated a “market outperform” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, August 31st. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $55.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Finally, Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $72.93.
Get Our Latest Report on CRISPR Therapeutics
CRISPR Therapeutics Profile
CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.
Read More
- Five stocks we like better than CRISPR Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report).
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
